Tainted medicine: Mass. moves to revoke pharmacists' licenses
The loss of licenses would be permanent. The FDA says it found evidence that NECC, which produced the tainted medicine, exceeded the terms of its license and violated production standards.
Massachusetts public health officials have moved to permanently pull the licenses of the three top pharmacists at a Bay State compounding pharmacy whose tainted medicine has been linked to more than 300 illnesses and 24 deaths in 17 states.Skip to next paragraph
Subscribe Today to the Monitor
The move coincided with the release of preliminary findings from state and US Food and Drug Administration inspectors, who say they found evidence that the company, the New England Compounding Center (NECC), violated the terms of its license and fell short of meeting internationally recognized standards for compounding pharmacies that produce sterile drugs. These standards form the basis for state regulations governing compounding pharmacies.
Typically, compounding pharmacies produce relatively small quantities of medicines whose dose or composition is tailored to meet the needs of patients unable to use mass-produced drugs. The pharmacies produce the drugs in response to prescriptions doctors provide.
In NECC's case, the company was making and selling sterile pharmaceuticals in large quantities but without specific prescriptions from an authorized physician or other health-care provider, according to a sampling of preliminary findings the state released on Tuesday.
"NECC was operating beyond the scope of their compounding license, instead acting as a manufacturer," said Madeleine Biondolillo, director of the Massachusetts Department of Public Health's Bureau for Healthcare Safety and Quality, at a press conference outlining the initial findings.
Nationally, 3,000 out of 7,500 compounding pharmacies produce sterile products, according to the International Academy of Compounding Pharmacies. According to Dr. Biondolillo, 25 compounding pharmacies in Massachusetts are qualified to produce sterile drugs.
State and federal investigators found a range of apparent NECC violations beyond mass-production. Among them:
• NECC shipped batches from two lots of the drug in question – an injectable steroid used to relieve pain – before it had results in hand from sterility tests the company performed on product. When the results came back, they indicated no contamination. Still, several sealed vials that came back under the company's recall of the product had black particles floating in them. Investigators are now looking into the thoroughness of the company's tests.
In addition, investigators found that when the company sterilized the steroids, they didn't operate the sterilization equipment long enough to meet minimum standards. The report also notes that the company failed to test the sterilization hardware to make sure it worked properly.
• A boiler next to the pharmacy's clean room had standing water under the boiler, reaching nearby walls. Water is a prime habitat for microbes, including the fungus associated with the outbreak of meningitis pegged to the tainted drug. Investigators have taken samples to see what sort of microbes the water holds.